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A. Gratwohl / Biol Blood Marrow Transplant 21 (2015) 579e582580In conclusion, recent years have witnessed acceptance of
and development of diverse approaches to haploidentical
transplantation. The original approach, transplantation of
high numbers of T celledepleted hematopoietic progenitor
cells and no post-transplantation immune suppression has,
with over 15 years’ follow-up, provided well-established
outcomes in adults and children and continues to offer
unique opportunities for innovative immunotherapeutic
strategies. All the recent reports of unmanipulated hap-
loidentical transplantation have fostered interest and debate
in the ﬁeld and, most importantly, served to substantially
extend its use. The new 2-step approach, as adopted by
Grosso et al. [1], provides very interesting results. It is to be
hoped they will be conﬁrmed in a longer follow-up and a
larger cohort of patients.
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Accepted 5 February 2015Kongtim et al. [1] from the department of stem cell
transplantation and cellular therapy at the MD Anderson
Cancer Center in Houston report convincing data showing
that a female donor for amale recipient can reduce the risk of
relapse after allogeneic hematopoietic stem cell trans-
plantation (HSCT) for acute myeloid leukemia. The positive
effects were most pronounced in young patients, under 50
years old, with advanced leukemia. The authors propose
considering a female donor as the preferred option in those
situations where relapse is of most concern; eg, for younger
patients with advanced disease stage or refractory disease.
They are optimistic about further studies with novel graft-
versus-host disease (GVHD) prevention methods. Such new
concepts might better exploit this speciﬁc advantage of an
HY mismatch; hence, leading to improved survival after
transplantation.The authors’ carefully conducted single-center study adds
to a long series of reports suggesting that minor histocom-
patibility antigens are as robust transplantation antigens as
their major histocompatibility antigen counterparts, the
human leukocyte antigens (HLA). HY, a group of Y chromo-
someeencoded antigens, are just among the most deﬁned
[2,3]. Multiple peptides have been identiﬁed. They can be
recognized by the host immune system and they can elicit a
humoral as well as a cellular immune response. In 1955,
Eichwald was the ﬁrst to describe a higher and faster rejec-
tion rate of male skin in female mice compared with those in
sex-identical pairs [4]. Twenty years later, Uphoff described
increased GVHD in male mice that underwent trans-
plantation with bone marrow from multiparous females
compared with those who received bone marrow from male
or nulliparous donors [5]. The importance of HYas a relevant
clinical entity in the human immune response was clearly
described by Goulmy in 1976 [6], followed by amore detailed
description of the effects of sex mismatch on rejection and
GVHD after transplantation for aplastic anemia [7].
Why then did it take more than 2 decades to establish the
role of HY for both GVHD and graft-versus-leukemia (GVL)
effects after HSCT [8] and to assess the role of HY in clinical
kidney transplantation [9,10]?Why then is gender mismatch
not integrated in the kidney donor allocation scheme [11]?
Why does the question about best donor selection in HSCT
prevail [1]?
The answer is, in part, simple. Too frequently, there is just
“only 1 donor available.” The slightly higher risk might still
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Figure 1. GVHD and GVL after allogeneic HSCT and outcome. The circle depicts
the 4 possibilities of GVHD-GVL combinations and their relative role on
outcome after an allogeneic HSCT: no GVHD/no GVL (white), GVH/no GVL
(yellow), GVHD and GVL (green), and no GVHD/GVL (blue). The graphs illus-
trate the respective outcome after HSCT: death from relapse (REL, blue), death
from transplantation-related mortality (TRM, yellow), and overall survival (OS,
white). GVL reduces the proportion of REL and GVHD increases the proportion
of TRM. Best OS can, therefore, be obtained in patients experiencing GVL but
no GVHD, with worst survival in patients with GVHD but no GVL (see text).
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transplantation strategy in the individual setting.
The answer is, in part, complex. There are always advan-
tages and disadvantages; nothing is only black or only white.
This is nicely illustrated in the ﬁeld of kidney transplantation.
The disadvantage of a male kidney for a female recipient is
equalized by the bigger male kidney with its higher nephron
load in the individual setting. The disadvantage of the male
recipient “missing” this speciﬁc male kidney takes place else-
where; hence, it is neglected in the decision-making process.
In HSCT, the advantage of GVL in preventing relapse after
HSCT might be overestimated. GVL and GVHD are inﬂuenced
by many factors, dependent and independent. For both, the
concept originally described by Billingham for GVHD holds
true [12]. There must be a recognizable antigenic difference
between the donor and recipient, the donor cells must
remain in the host (security of tenure), and the donor cells
must be able to mount an immune response. GVHD and GVL
can, but must not, develop in parallel (Figure 1). None might
be present in the absence of an antigenic difference or when
no response evolves (no GVHD/no GVL). The target antigen
might only be expressed on host tissue but not on leukemic
cells (GVHD/no GVL). They might be expressed on both, host
tissue and leukemic cells, as is the case for HY (GVH and
GVL), or they might be restricted to hematopoietic or
leukemic cells only (no GVHD/GVL). Obviously, the latter
represents the ideal situation. There are clear indications that
it exists, in acute myeloid leukemia especially [13], but it
remains scarce. Few true leukemia antigens are identiﬁed; in
addition, leukemic cells have the capacity to lose their HLA
antigens, to escape immune recognition, and to hide [14].
Multiple studies have analyzed the respective role of
gender mismatch after HSCT. Results appear conclusive in
larger series. There is a higher likelihood of rejection for male
donor/female recipient pairs, especially in nonmalignant
diseases. There is, vice versa, a higher likelihood of GVHD and
transplantation-related mortality (TRM) in female donor/
male recipient pairs and, consistently, an associated lower
relapse rate (REL). This has been observed in all disease
categories and is independent from donor type, stem cell
source, or conditioning intensity [13,15-17]. The relative
negative impact on survival of the net difference between
TRM and REL on overall survival can vary substantially from
disease to disease and can range from less than 5% in acute
lymphoblastic leukemia to >20% in chronic myeloid leuke-
mia [15]. So far, it has never been reported to be an advantage
for GVL; it becomes to a nonsigniﬁcant difference for patients
with highly advanced disease, with mismatched trans-
plantations, or with female donors below the age of 20 years.
Thus, the report from Kongtim et al. [1] ﬁts the literature.
Their tempting conclusions are easily understood, but
questions remain. They speculate that for patients younger
than50 years of agebutwith high-risk disease, the net beneﬁt
of GVLmight win in overall survival. Today, in young patients
with an excellent performance score, a well-matched donor,
and no comorbidities, the risk for TRM is indeed low. A
reduction of the excessive relapse incidence via GVL appears
attractive. This might indeed be the case in the early post-
transplantation period, when the reduction of REL might be
higher than themodest increase in the lowTRM rate. This has
been shown by the large European Society for Blood and
Marrow Transplantation analysis. Beyond 3 years, however,
relapse risk remained similar between the 2 groups, whereas
GVHD-associated TRM continued to increase at a higher rate
in the female donor/male recipient group. At 5 years, allpotential beneﬁt was lost [13,15]. It is unlikely, as well, that
novel GVHD prevention approaches, as stipulated by the au-
thors, might alter the balance, as long as they cannot separate
GVL and GVHD; the same difference between the 2 groups in
REL and TRMwere observed in T celledepleted as well as in T
cellereplete transplantations [13,15].
The authors correctly ask for more studies of new GVHD
prevention methods. That’s not enough. There is an urgent
need for large multicenter studies on disease mechanisms.
Some recipients of HLA-matched transplants never develop
GVHD. If theycould be identiﬁed before transplantation,GVHD
prevention could be omitted. Similarly, some male patients
with a female donor never get any signs of GVHD. Why is this
the case?Howcould they be identiﬁedbefore transplantation?
There are some indications that a disturbed balance in
regulatory T cells might be associated with an aberrant
strong or absent immune response to HY [18-21] and that
application of such speciﬁc regulatory T cells might shift the
balance to protection from GVHD. With better insight, the
rate of recurrent miscarriage in affected pregnant women
might be reduced; low-risk female donor/male recipient
pairs could be identiﬁed. It might then not only justify a fe-
male donor/male recipient HSCT in a young patient with
advanced leukemia, it might also justify the transplantation
early on in the disease course, even for less than high-risk
leukemia [22]. Early and low risk transplantations can help
to save lives and resources [23].
There are clear prospects for the future. For the time be-
ing, it remains wise to stick to the current habit. A bad guy,
GVHD, might have a friendly facedGVL; however, he re-
mains a bad guy. HSCT, whatever the indication, should
provide a better outcome regarding long-term survival,
quality of life, and costs compared with any other non-
transplantation strategy. If a choice can be made, a male
donor should be preferred for a male recipient. Unrelated
donor registries should continue to focus recruitment stra-
tegies on young male donors.ACKNOWLEDGMENTS
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